LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Verve Therapeutics Inc

Fermé

11.3 0.53

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.24

Max

11.31

Chiffres clés

By Trading Economics

Revenu

19M

-31M

Ventes

20M

33M

BPA

-0.35

Marge bénéficiaire

-94.108

Employés

274

EBITDA

19M

-35M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+34.34% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

604M

992M

Ouverture précédente

10.77

Clôture précédente

11.3

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Verve Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 juin 2025, 11:56 UTC

Acquisitions, Fusions, Rachats

Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion

17 juin 2025, 14:02 UTC

Acquisitions, Fusions, Rachats

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know. -- Barrons.com

17 juin 2025, 12:12 UTC

Acquisitions, Fusions, Rachats

Eli Lilly's $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring 77%. What to Know. -- Barrons.com

17 juin 2025, 11:01 UTC

Acquisitions, Fusions, Rachats

This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid -- Barrons.com

17 juin 2025, 10:47 UTC

Acquisitions, Fusions, Rachats

Eli Lilly: Total Potential Consideration of Up to $13.50 Per Shr in Cash Without Interest >LLY

17 juin 2025, 10:47 UTC

Acquisitions, Fusions, Rachats

Eli Lilly: Considering Also Includes One Non-Tradeable Contingent Value Right Per Shr That Entitles Holder to Receive Up to an Additional $3 Per Shr >LLY

17 juin 2025, 10:46 UTC

Acquisitions, Fusions, Rachats

Eli Lilly Will Commence Tender Offer to Acquire All Outstanding Shrs of Verve for Purchase Price of $10.50 Per Shr in Cash >LLY

17 juin 2025, 10:45 UTC

Acquisitions, Fusions, Rachats

Lilly To Acquire Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

17 juin 2025, 09:33 UTC

Acquisitions, Fusions, Rachats

Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%. -- Barrons.com

Comparaison

Variation de prix

Verve Therapeutics Inc prévision

Objectif de Prix

By TipRanks

34.34% hausse

Prévisions sur 12 Mois

Moyen 15.06 USD  34.34%

Haut 24 USD

Bas 11 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

4

Achat

6

Maintien

0

Vente

Score Technique

By Trading Central

4.1501 / 5.16Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Very Strong Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.